Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

CHICAGO -- For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of apixaban (Eliquis) was just as effective as a higher dose -- and safer, the ...

A lower apixaban dose is indicated in patients with an eGFR less than 30 mL/min/1.73 m2, regardless of dialysis status. Impaired kidney function is the principal predictor of hemorrhage in patients ...

For patients with HIV and atrial fibrillation, this study found that apixaban was associated with less bleeding when compared with warfarin and rivaroxaban. Data remain inconclusive regarding ...

Apixaban may be safer and more effective than rivaroxaban for treating nonvalvular atrial fibrillation (AF), a new observational study suggests. The study, one of the largest to compare the two drugs ...

Observational data suggest apixaban leads to fewer thromboembolic events but higher bleeding risk, highlighting the need for individualized decision-making in dialysis patients.

Eliquis Offered to Cash-Paying Patients at More Than 40% Discount to Current List Price, Sotyktu at More Than 80% Discount to Current List Price PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb ...